These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 9043025

  • 21. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
    Grossi F, Spizzo R, Bordo D, Cacitti V, Valent F, Rossetto C, Follador A, Di Terlizzi S, Aita M, Morelli A, Fasola G, Consiglieri C, Ceschia T, Beltrami CA, Belvedere O.
    J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
    [Abstract] [Full Text] [Related]

  • 22. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
    Ko E, Kim Y, Cho EY, Han J, Shim YM, Park J, Kim DH.
    Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S, Schleucher N, Weber R, Neumann R, Seeber S.
    Oncol Rep; 2003 Mar; 10(2):475-82. PubMed ID: 12579292
    [Abstract] [Full Text] [Related]

  • 24. p185(HER-2/neu) and p21(CIP1/WAF1) expression in primary tumors and lymph node metastases in non-small cell lung cancer.
    Akita K, Inagaki H, Sato S, Niimi T, Maeda H, Ninomiya S, Achiwa H, Kawaguchi H, Yamakawa Y, Fujii Y, Shimizu S, Eimoto T, Ueda R.
    Jpn J Cancer Res; 2002 Sep; 93(9):1007-11. PubMed ID: 12359054
    [Abstract] [Full Text] [Related]

  • 25. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [Abstract] [Full Text] [Related]

  • 26. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms.
    Lee HJ, Seol HS, Kim JY, Chun SM, Suh YA, Park YS, Kim SW, Choi CM, Park SI, Kim DK, Kim YH, Jang SJ.
    Ann Surg Oncol; 2013 Jan; 20(1):200-8. PubMed ID: 22915320
    [Abstract] [Full Text] [Related]

  • 27. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, Marie B, Farré G, Labib T, Pottier G, Sesboüé R, Bronner C, Vignaud JM, Martinet Y, Martinet N.
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [Abstract] [Full Text] [Related]

  • 28. [P185 (Neu) oncoprotein in the prognosis of bladder carcinoma. Experience of 5 years].
    Moreno Sierra J, Maestro de las Casas ML, Redondo González E, Fernández Pérez C, del Barco Barriuso V, Sanz Casla MT, Blanco Jiménez E, Silmi Moyano A, Resel Estévez L.
    Arch Esp Urol; 2000 Apr; 53(3):238-44. PubMed ID: 10851729
    [Abstract] [Full Text] [Related]

  • 29. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
    Al-Saad S, Al-Shibli K, Donnem T, Andersen S, Bremnes RM, Busund LT.
    J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
    [Abstract] [Full Text] [Related]

  • 30. KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.
    Sullivan I, Salazar J, Arqueros C, Andrés M, Sebio A, Majem M, Szafranska J, Martínez E, Páez D, López-Pousa A, Baiget M, Barnadas A.
    Clin Transl Oncol; 2017 Jul; 19(7):884-890. PubMed ID: 28150169
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
    Hou X, Li Y, Luo RZ, Fu JH, He JH, Zhang LJ, Yang HX.
    Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Cytoplasmic and nuclear parathyroid hormone-related proteins are opposing prognostic factors in patients with non-small-cell lung cancer who have undergone curative resection.
    Wu CE, Wang CW, Huang WK, Yang CT, Wu YC, Hou MM, Hsieh CH, Hsieh JJ, Cheng HY, Hsu T, Chang JW.
    Jpn J Clin Oncol; 2015 Mar; 45(3):267-73. PubMed ID: 25480982
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. High temperature requirement A3 (HTRA3) expression predicts postoperative recurrence and survival in patients with non-small-cell lung cancer.
    Zhao J, Zhang J, Zhang X, Feng M, Qu J.
    Oncotarget; 2016 Jun 28; 7(26):40725-40734. PubMed ID: 27166271
    [Abstract] [Full Text] [Related]

  • 39. Risk Factors for Local and Distant Recurrence After Surgical Treatment in Patients With Non-Small-Cell Lung Cancer.
    Dziedzic DA, Rudzinski P, Langfort R, Orlowski T, Polish Lung Cancer Study Group (PLCSG).
    Clin Lung Cancer; 2016 Sep 28; 17(5):e157-e167. PubMed ID: 26831834
    [Abstract] [Full Text] [Related]

  • 40. Detection of increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans.
    Brandt-Rauf PW, Luo JC, Carney WP, Smith S, De Vivo I, Milling C, Hemminki K, Koskinen H, Vainio H, Neugut AI.
    Int J Cancer; 1994 Feb 01; 56(3):383-6. PubMed ID: 7906254
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.